From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity

被引:0
作者
Flores, Hannah E. [1 ]
Burgos, Eduar Fernando Pinzon [1 ]
Ortega, Sigrid Camacho [1 ]
Heredia, Alonso [1 ]
Chua, Joel V. [1 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, Div Clin Care & Res, Baltimore, MD 21201 USA
关键词
correlates of protection; Flaviviridae; Dengue virus; Japanese encephalitis virus; yellow fever virus; West Nile virus; Zika virus; WEST-NILE-VIRUS; JAPANESE ENCEPHALITIS-VIRUS; TETRAVALENT DENGUE VACCINE; NEUTRALIZING HUMAN-ANTIBODIES; YELLOW-FEVER VACCINE; ZIKA VIRUS; DOUBLE-BLIND; MONOCLONAL-ANTIBODIES; STRUCTURAL BASIS; DEPENDENT ENHANCEMENT;
D O I
10.3390/vaccines13050449
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Flaviviruses are arthropod-borne RNA viruses that can cause a wide range of human diseases, from mild symptoms to severe illness with multiorgan failure and death. Effective prevention of these diseases relies on identifying reliable vaccine targets, typically measured by correlates of protection (CoPs), which help indicate host immunity after vaccination. Current vaccines primarily focus on neutralizing antibodies (nAbs) against the viral envelope E protein, though emerging evidence suggests other potential targets may also be effective in disease prevention. Additionally, there is growing evidence of cross-protection between different flaviviruses when immunity to one virus is achieved, although this can be limited by antibody-dependent enhancement. This review examines the current understanding of flavivirus immunity, CoPs, and the potential for cross-protection in the context of existing vaccine strategies.
引用
收藏
页数:22
相关论文
共 163 条
[1]   MRL Strains Have a BAFFR Mutation without Functional Consequence [J].
Allman, Windy R. ;
Liu, Lunhua ;
Coleman, Adam S. ;
Akkoyunlu, Mustafa .
PLOS ONE, 2016, 11 (05)
[2]   Questions regarding the safety and duration of immunity following live yellow fever vaccination [J].
Amanna, Ian J. ;
Slifka, Mark K. .
EXPERT REVIEW OF VACCINES, 2016, 15 (12) :1519-1533
[3]   Neutralizing antibodies from prior exposure to dengue virus negatively correlate with viremia on re-infection [J].
Anantharaj, Anbalagan ;
Agrawal, Tanvi ;
Shashi, Pooja Kumari ;
Tripathi, Alok ;
Kumar, Parveen ;
Khan, Imran ;
Pareek, Madhu ;
Singh, Balwant ;
Pattabiraman, Chitra ;
Kumar, Saurabh ;
Pandey, Rajesh ;
Chandele, Anmol ;
Lodha, Rakesh ;
Whitehead, Stephen S. ;
Medigeshi, Guruprasad R. .
COMMUNICATIONS MEDICINE, 2023, 3 (01)
[4]   Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro [J].
Anderson, JF ;
Rahal, JJ .
EMERGING INFECTIOUS DISEASES, 2002, 8 (01) :107-108
[5]  
[Anonymous], 2013, Wkly Epidemiol Rec, V88, P269
[6]  
[Anonymous], IDCRC Launches Clinical Trial to Study the Safety and Immunogenicity of an Inactivated West Nile Virus vaccine. Infectious Diseases Clinical Research Consortium. Accessed 22 April, P2025
[7]  
[Anonymous], 2015, Zika: Symptoms, Prevention and Treatments
[8]  
[Anonymous], 2025, Clinical Signs and Symptoms of Zika Virus Disease
[9]  
[Anonymous], 2024, Japanese Encephalitis
[10]   Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic Epitope [J].
Austin, S. Kyle ;
Dowd, Kimberly A. ;
Shrestha, Bimmi ;
Nelson, Christopher A. ;
Edeling, Melissa A. ;
Johnson, Syd ;
Pierson, Theodore C. ;
Diamond, Michael S. ;
Fremont, Daved H. .
PLOS PATHOGENS, 2012, 8 (10)